Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENL101 in Relapsed or Refractory T-LBL/ALL
NCT06136364Phase 1Recruiting
- Sponsor
- Senlang Bio
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SENL101 in T cell lymphoblastic lymphoma (T-LBL) and t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Senlang Bio. Primary endpoint: Incidence and severity of adverse events. Started Aug 2023; status: recruiting.
02
Drugs
SENL101
03
Conditions
T cell lymphoblastic lymphoma (T-LBL)t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT06136364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136364.